TABLE 4.
MICs of beta-lactam antimicrobials for recipient strains before acquisition of pNVI1292/IncK or pNVI2798/IncI1 plasmid, and for transconjugants after acquisition of pNVI1292/IncK and pNVI2798/IncI1 plasmids
| Recipient/transconjugant strain (plasmid) | MIC (epidemiological cutoff value for antimicrobial) (mg/liter)a |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FOX (8) | ETP (0.06) | IMI (0.5) | MERO (0.12) | TAZ (0.5) | FEP (0.12) | F/C (0.25/4) | T/C (0.5/4) | FOT (0.25) | TRM (NA) | |
| E. coli 6927-5 | 4 | ≤0.015 | ≤0.12 | ≤0.03 | ≤0.25 | ≤0.06 | ≤0.06/4 | ≤0.012/4 | ≤0.25 | 4 |
| E. coli 6927-5(IncK) | 32 | 0.03 | ≤0.12 | ≤0.03 | 8 | 0.12 | 4/4 | 4/4 | 4 | 4 |
| E. coli 6927-5(IncI1) | 64 | 0.03 | ≤0.12 | ≤0.03 | 16 | 0.25 | 4/4 | 8/4 | 8 | 4 |
| S. marcescens 3306 | 16 | ≤0.015 | 0.5 | 0.06 | ≤0.25 | ≤0.06 | ≤0.06/4 | 0.5/4 | ≤0.25 | 8 |
| S. marcescens 3306(IncK) | 32 | 0.03 | 0.5 | 0.06 | 8 | 0.25 | 4/4 | 8/4 | 4 | 8 |
| S. marcescens 3307 | 8 | ≤0.015 | 0.5 | ≤0.03 | ≤0.25 | ≤0.06 | ≤0.06/4 | ≤0.12/4 | ≤0.25 | 8 |
| S. marcescens 3307(IncK) | 32 | 0.06 | 0.5 | 0.6 | 8 | 0.25 | 8/4 | 8/4 | 4 | 8 |
| S. proteamaculans 5685 | 4 | ≤0.015 | 0.25 | ≤0.03 | ≤0.25 | ≤0.06 | ≤0.06/4 | ≤0.12/4 | ≤0.25 | 4 |
| S. proteamaculans 5685(IncK) | 64 | ≤0.015 | 0.25 | ≤0.03 | 2 | 0.12 | 4/4 | 1/4 | 8 | 4 |
a
FOX, cefoxitin; ETP, ertapenem; IMI, imipenem; MERO, meropenem; TAZ, ceftazidime; FEP, cefepime; F/C, cefotaxime-clavulanic acid; T/C, ceftazidime-clavulanic acid; FOT, cefotaxime; TRM, temocillin; NA, not available.